Form 144 Nautilus Biotechnology, Filed by: Godwin Mary E.
Nautilus Biotechnology, Inc. (NAUT)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
NAUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAUT alerts
High impacting Nautilus Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
NAUT
News
- With 32% ownership, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders have a lot riding on the company's future [Yahoo! Finance]Yahoo! Finance
- Nautilus Biotechnology, Inc. (NASDAQ: NAUT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $1.75 price target on the stock.MarketBeat
- Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research’s Distinguished Investigator AwardGlobeNewswire
- Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare ConferenceGlobeNewswire
- Nautilus Biotechnology Reports Third Quarter 2024 Financial ResultsGlobeNewswire
NAUT
Earnings
- 10/29/24 - Beat
NAUT
Sec Filings
- 12/17/24 - Form 144
- 12/9/24 - Form 144
- 12/3/24 - Form 144
- NAUT's page on the SEC website